| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,398,000 |
| Market
Cap: |
283.66(M) |
| Last
Volume: |
821,939 |
Avg
Vol: |
693,736 |
| 52
Week Range: |
$3.38 - $6.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 803 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
121,098 |
121,098 |
148,134 |
388,157 |
| Total Sell Value |
$513,345 |
$513,345 |
$684,141 |
$2,735,436 |
| Total People Sold |
5 |
5 |
6 |
8 |
| Total Sell Transactions |
10 |
10 |
14 |
33 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Watkins Thomas |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
40,323 |
|
- |
|
| Mitchell Stephen Ray |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,200 |
|
- |
|
| Chrousos Phaedra |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
|
- |
|
| Dugan Richard W |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
45,641 |
|
- |
|
| Ward Anne Sempowski |
Director |
– • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Watkins Thomas |
Director |
– • – |
2020-05-29 |
4 |
S |
$11.50 |
$111,286 |
D/D |
(9,677) |
35,323 |
|
-0% |
|
| Watkins Thomas |
Director |
– • – |
2020-05-29 |
4 |
OE |
$7.38 |
$110,700 |
D/D |
15,000 |
45,000 |
|
- |
|
| Dugan Richard W |
Director |
– • – |
2020-05-28 |
4 |
S |
$11.04 |
$111,806 |
D/D |
(10,129) |
40,641 |
|
4% |
|
| Dugan Richard W |
Director |
– • – |
2020-05-28 |
4 |
OE |
$7.38 |
$110,700 |
D/D |
15,000 |
50,770 |
|
- |
|
| Moran Kevin Patrick |
VP, Acting CFO & TreasurerOffi |
• – – |
2020-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
60,753 |
|
31% |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2020-03-03 |
4 |
S |
$10.76 |
$63,359 |
D/D |
(5,889) |
186,869 |
|
-2% |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2020-03-03 |
4 |
S |
$10.98 |
$56,544 |
D/D |
(5,152) |
1,278,999 |
|
-2% |
|
| Williams Timothy |
SVP & General Counsel |
• – – |
2020-03-03 |
4 |
S |
$10.51 |
$13,004 |
D/D |
(1,237) |
83,040 |
|
-2% |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2020-03-03 |
4 |
S |
$10.66 |
$58,984 |
D/D |
(5,535) |
159,473 |
|
-2% |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2020-03-02 |
4 |
S |
$10.19 |
$132,087 |
D/D |
(12,968) |
192,758 |
|
-3% |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2020-03-02 |
4 |
S |
$10.57 |
$110,211 |
D/D |
(10,428) |
1,284,151 |
|
-3% |
|
| Reverberi Gian Piero |
SVP & Chief Commercial Officer |
• – – |
2020-03-02 |
4 |
S |
$10.18 |
$14,755 |
D/D |
(1,450) |
165,384 |
|
-3% |
|
| Williams Timothy |
SVP & General Counsel |
• – – |
2020-03-02 |
4 |
S |
$10.30 |
$32,436 |
D/D |
(3,148) |
84,277 |
|
-3% |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2020-03-02 |
4 |
S |
$10.04 |
$122,686 |
D/D |
(12,223) |
165,008 |
|
-3% |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2020-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
177,231 |
|
- |
|
| Williams Timothy |
SVP & General Counsel |
• – – |
2020-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
87,425 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2020-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
1,294,579 |
|
- |
|
| Wijkstrom Joakim |
SVP, Chief Marketing Officer |
• – – |
2020-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
60,000 |
|
- |
|
| Jones Aranthan Ii |
Chief Corp. Affairs Officer |
• – – |
2020-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
90,000 |
|
- |
|
| Reverberi Gian Piero |
SVP & Chief Commercial Officer |
• – – |
2020-01-02 |
4 |
S |
$16.06 |
$18,551 |
D/D |
(1,155) |
166,834 |
|
28% |
|
549 Records found
|
|
Page 6 of 22 |
|
|
0.14 (3.12%) 
